Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Arch Biopartners Inc

ARCH.V ✓ COMPLIANT ☆ Track — members

TSX Venture · Healthcare · Pharmaceuticals ·

Canada Micro Cap Analyst: N/A

Last Close

$0.80

▼ -3.48%

Market Cap $54.13M · Vol 24.41K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$54.13M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

68.18

Momentum

Beta

1.49

vs Market

52W High

$1.24

35.89% below

52W Low

$0.28

180.35% above

Volume

24.41K

Avg 65.02K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

81.62%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Arch Biopartners Inc (ARCH.V) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ARCH.V pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+4.72%

+32.14%

+158.14%

+16.84%

YTD

-9.02%

-34.32%

-45.73%

-38.67%

Financials & Valuation

TTM · Annual

Total Revenue	$198.23K
Net Income	$-1,115,474.00
Revenue Growth (YoY)	N/A
Gross Margin	100.00%
Operating Margin	-449.97%
Net Profit Margin	-562.70%
ROE	N/A
ROA · ROIC	-298.56% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	304.31
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	67.93M

Technical Indicators

50-Day SMA	$0.58
200-Day SMA	$0.61
RSI (14)	68.18
Beta	1.49
52-Week High	$1.24
52-Week Low	$0.28

Volume Today	24.41K
Avg Daily Volume (30D)	65.02K
Relative Volume	0.38x
Volatility (10D)	110.36
Volatility (30D)	86.28
Free Float	81.62%

Analyst Consensus

N/A

Current Price $0.80

Mean Target N/A

52W Low$0.28 52W High$1.24

Current

Target

$0.28 $1.24

Current Analyst target

· 0 analysts

Identifiers

ExchangeTSX Venture

FIGIBBG001SFS5M7

ISINCA03938C1041

CountryCanada

Sub-IndustryPharmaceuticals (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Arch Biopartners Inc. is a therapeutic biotech company developing novel drugs for acute and chronic kidney diseases. The Company is advancing an integrated pipeline that includes new treatments targeting inflammation and toxin-induced kidney injury. Its programs include a pre-clinical chronic kidney disease platform targeting interleukin-32 (IL-32), LSALT peptide, a dipeptidase-1 (DPEP1) inhibitor in Phase II for preventing cardiac surgery-associated acute kidney injury, and cilastatin, a repurposed drug in Phase II for preventing toxin-induced kidney damage. These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting millions of patients worldwide. Its LSALT Peptide and cilastatin, are being developed to target kidney injury caused by inflammation or toxins respectively, which are both significant unmet medical needs.